Michael E. Nassif

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors, Christiane E. Angermann, John R. Teerlink et al. · Nature Medicine · 2022 · 895 citations · Full text

Medicine, Cardiology, Pharmacology +15

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Michael E. Nassif, Sheryl L. Windsor, Barry A. Borlaug et al. · Nature Medicine · 2021 · 604 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction

Michael E. Nassif, Sheryl L. Windsor, Fengming Tang et al. · Circulation · 2019 · 427 citations

Medicine, Cardiology, Pharmacology +17

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Martin S. Maron, Ahmad Masri, Michael E. Nassif et al. · New England Journal of Medicine · 2024 · 282 citations · Full text

Medicine, Cardiology, Pharmacotherapy +14

Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure

Michael E. Nassif, Mohammed Qintar, Sheryl L. Windsor et al. · Circulation · 2021 · 274 citations · Full text

Medicine, Cardiology, Pharmacology +15